Bicycle Therapeutics plc
BCYCHealthcare|Biotechnology|GB
$3.61
+0.13 (+3.74%)
Tangible Book / Share
$7.22
Cash / Share
$6.72
Clinical Trials (10)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06225596 Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) | Metastatic Urothelial Cancer | P2 | Active | 375 | RCT, Open-label | Zelenectide pevedotin, Zelenectide pevedotin, Pembrolizumab, Gemcitabine + cisplatin Or carboplatin, Avelumab |
| NCT04561362 Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms | P1P2 | Active | 329 | Open-label | BT8009, Pembrolizumab |
| NCT05163041 Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression | Advanced Solid Tumor | P1P2 | Active | 200 | Open-label | BT7480, Nivolumab |
| NCT07450859 A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Ductal Adenocarcinoma (PDAC) | P2 | Recruiting | 39 | Open-label | nuzefatide pevedotin (BT5528) |
| NCT04180371 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer | P1P2 | Active | 288 | Open-label | BT5528, Nivolumab |
| NCT06840483 Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer | Breast Cancer | P2 | Active | 66 | Open-label | Zelenectide pevedotin (BT8009) |
| NCT06933329 Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer | Non-Small Cell Lung Cancer | P2 | Active | 73 | Open-label | Zelenectide pevedotin |
| NCT05644587 Novel Induction to Buprenorphine/Naloxone | Opioid Use Disorder, Opioid Use | P4 | Terminated | 33 | RCT, Open-label | buprenorphine/naloxone |
| NCT03486730 BT1718 in Patients with Advanced Solid Tumours. | Advanced Solid Tumours, Non-Small Cell Lung Cancer | P1P2 | Completed | 72 | Open-label | BT1718 |
| NCT07681674 Bicycle Continued Access Protocol (BiCAP) for Participants Receiving a Bicycle Investigational Product | Advanced Solid Tumors | P2 | Not Yet Recruiting | 16 | Open-label | Zelenectide pevedotin, BT7480, Nuzefatide pevedotin |